Discovery and Optimization of Imidazopyridine-Based Inhibitors of Diacylglycerol Acyltransferase 2 (DGAT2)

Journal of Medicinal Chemistry

Volumn 58, Issue 18, 2015, Pages 7173-7185

  Futatsugi, Kentaro ^a   Kung, Daniel W ^a   Orr, Suvi T M ^a   Cabral, Shawn ^a   Hepworth, David ^a   Aspnes, Gary ^a   Bader, Scott ^a   Bian, Jianwei ^a   Boehm, Markus ^a   Carpino, Philip A ^a   Coffey, Steven B ^a   Dowling, Matthew S ^a   Herr, Michael ^a   Jiao, Wenhua ^a   Lavergne, Sophie Y ^a   Li, Qifang ^a   Clark, Ronald W ^a   Erion, Derek M ^a   Kou, Kou ^a   Lee, Kyuha ^a   Pabst, Brandon A ^a   Perez, Sylvie M ^a   Purkal, Julie ^a   Jorgensen, Csilla C ^a   Goosen, Theunis C ^a   Gosset, James R ^a   Niosi, Mark ^a   Pettersen, John C ^a   Pfefferkorn, Jeffrey A ^a   Ahn, Kay ^a   Goodwin, Bryan ^a   more..

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIACYLGLYCEROL ACYLTRANSFERASE 2; IMIDAZOPYRIDINE DERIVATIVE; PF 06424439; UNCLASSIFIED DRUG; CYCLOPROPANE DERIVATIVE; DIACYLGLYCEROL ACYLTRANSFERASE; IMIDAZOLE DERIVATIVE; LOW DENSITY LIPOPROTEIN RECEPTOR; PF-06424439; PYRIDINE DERIVATIVE; PYRROLIDINE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG EXCRETION; DRUG GLUCURONIDATION; DRUG METABOLISM; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; DYSLIPIDEMIA; ENZYME INHIBITION; HUMAN; HUMAN CELL; MALE; NONHUMAN; RAT; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMISTRY; DOG; DRUG EFFECTS; DYSLIPIDEMIAS; GENETICS; KNOCKOUT MOUSE; LIPID METABOLISM; LIVER CELL; METABOLISM; SF9 CELL LINE; SPODOPTERA; SPRAGUE DAWLEY RAT; STEREOISOMERISM; STRUCTURE ACTIVITY RELATION;

ANIMALS; CYCLOPROPANES; DIACYLGLYCEROL O-ACYLTRANSFERASE; DOGS; DYSLIPIDEMIAS; HEPATOCYTES; HUMANS; IMIDAZOLES; LIPID METABOLISM; MALE; MICE, KNOCKOUT; PYRIDINES; PYRROLIDINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, LDL; SF9 CELLS; SPODOPTERA; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84942251348     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/acs.jmedchem.5b01006     Document Type: Article

References (62)

1. Raised cholesterol: Situation and Trends. Global Health Observatory (GHO) Data; World Health Organization: Geneva, 2015; http://www.who.int/gho/ncd/risk-factors/cholesterol-text/en/
2. Baigent, C.; Keech, A.; Kearney, P. M.; Blackwell, L.; Buck, G.; Pollicino, C.; Kirby, A.; Sourjina, T.; Peto, R.; Collins, R.; Simes, R.; Cholesterol Treatment Trialists' (CTT) Collaborators Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins Lancet 2005, 366 (9493) 1267-1278 10.1016/S0140-6736(05)67394-1
3. Ridker, P. M.; Genest, J.; Boekholdt, S. M.; Libby, P.; Gotto, A. M.; Nordestgaard, B. G.; Mora, S.; MacFadyen, J. G.; Glynn, R. J.; Kastelein, J. J.; JUPITER Trial Study Group HDL cholesterol and residual risk of first cardiovascular events after treatment with potent statin therapy: an analysis from the JUPITER trial Lancet 2010, 376 (9738) 333-339 10.1016/S0140-6736(10)60713-1
4. Sampson, U. K.; Fazio, S.; Linton, M. F. Residual cardiovascular risk despite optimal LDL cholesterol reduction with statins: the evidence, etiology, and therapeutic challenges Curr. Atheroscler. Rep. 2012, 14 (1) 1-10 10.1007/s11883-011-0219-7
5. Do, R.; Willer, C. J.; Schmidt, E. M.; Sengupta, S.; Gao, C.; Peloso, G. M.; Gustafsson, S.; Kanoni, S.; Ganna, A.; Chen, J.; Buchkovich, M. L.; Mora, S.; Beckmann, J. S.; Bragg-Gresham, J. L.; Chang, H. Y.; Demirkan, A.; Den Hertog, H. M.; Donnelly, L. A.; Ehret, G. B.; Esko, T.; Feitosa, M. F.; Ferreira, T.; Fischer, K.; Fontanillas, P.; Fraser, R. M.; Freitag, D. F.; Gurdasani, D.; Heikkila, K.; Hypponen, E.; Isaacs, A.; Jackson, A. U.; Johansson, A.; Johnson, T.; Kaakinen, M.; Kettunen, J.; Kleber, M. E.; Li, X.; Luan, J.; Lyytikainen, L. P.; Magnusson, P. K.; Mangino, M.; Mihailov, E.; Montasser, M. E.; Muller-Nurasyid, M.; Nolte, I. M.; O'Connell, J. R.; Palmer, C. D.; Perola, M.; Petersen, A. K.; Sanna, S.; Saxena, R.; Service, S. K.; Shah, S.; Shungin, D.; Sidore, C.; Song, C.; Strawbridge, R. J.; Surakka, I.; Tanaka, T.; Teslovich, T. M.; Thorleifsson, G.; Van den Herik, E. G.; Voight, B. F.; Volcik, K. A.; Waite, L. L.; Wong, A.; Wu, Y.; Zhang, W.; Absher, D.; Asiki, G.; Barroso, I.; Been, L. F.; Bolton, J. L.; Bonnycastle, L. L.; Brambilla, P.; Burnett, M. S.; Cesana, G.; Dimitriou, M.; Doney, A. S.; Doring, A.; Elliott, P.; Epstein, S. E.; Eyjolfsson, G. I.; Gigante, B.; Goodarzi, M. O.; Grallert, H.; Gravito, M. L.; Groves, C. J.; Hallmans, G.; Hartikainen, A. L.; Hayward, C.; Hernandez, D.; Hicks, A. A.; Holm, H.; Hung, Y. J.; Illig, T.; Jones, M. R.; Kaleebu, P.; Kastelein, J. J.; Khaw, K. T.; Kim, E.; Klopp, N.; Komulainen, P.; Kumari, M.; Langenberg, C.; Lehtimaki, T.; Lin, S. Y.; Lindstrom, J.; Loos, R. J.; Mach, F.; McArdle, W. L.; Meisinger, C.; Mitchell, B. D.; Muller, G.; Nagaraja, R.; Narisu, N.; Nieminen, T. V.; Nsubuga, R. N.; Olafsson, I.; Ong, K. K.; Palotie, A.; Papamarkou, T.; Pomilla, C.; Pouta, A.; Rader, D. J.; Reilly, M. P.; Ridker, P. M.; Rivadeneira, F.; Rudan, I.; Ruokonen, A.; Samani, N.; Scharnagl, H.; Seeley, J.; Silander, K.; Stancakova, A.; Stirrups, K.; Swift, A. J.; Tiret, L.; Uitterlinden, A. G.; van Pelt, L. J.; Vedantam, S.; Wainwright, N.; Wijmenga, C.; Wild, S. H.; Willemsen, G.; Wilsgaard, T.; Wilson, J. F.; Young, E. H.; Zhao, J. H.; Adair, L. S.; Arveiler, D.; Assimes, T. L.; Bandinelli, S.; Bennett, F.; Bochud, M.; Boehm, B. O.; Boomsma, D. I.; Borecki, I. B.; Bornstein, S. R.; Bovet, P.; Burnier, M.; Campbell, H.; Chakravarti, A.; Chambers, J. C.; Chen, Y. D.; Collins, F. S.; Cooper, R. S.; Danesh, J.; Dedoussis, G.; de Faire, U.; Feranil, A. B.; Ferrieres, J.; Ferrucci, L.; Freimer, N. B.; Gieger, C.; Groop, L. C.; Gudnason, V.; Gyllensten, U.; Hamsten, A.; Harris, T. B.; Hingorani, A.; Hirschhorn, J. N.; Hofman, A.; Hovingh, G. K.; Hsiung, C. A.; Humphries, S. E.; Hunt, S. C.; Hveem, K.; Iribarren, C.; Jarvelin, M. R.; Jula, A.; Kahonen, M.; Kaprio, J.; Kesaniemi, A.; Kivimaki, M.; Kooner, J. S.; Koudstaal, P. J.; Krauss, R. M.; Kuh, D.; Kuusisto, J.; Kyvik, K. O.; Laakso, M.; Lakka, T. A.; Lind, L.; Lindgren, C. M.; Martin, N. G.; Marz, W.; McCarthy, M. I.; McKenzie, C. A.; Meneton, P.; Metspalu, A.; Moilanen, L.; Morris, A. D.; Munroe, P. B.; Njolstad, I.; Pedersen, N. L.; Power, C.; Pramstaller, P. P.; Price, J. F.; Psaty, B. M.; Quertermous, T.; Rauramaa, R.; Saleheen, D.; Salomaa, V.; Sanghera, D. K.; Saramies, J.; Schwarz, P. E.; Sheu, W. H.; Shuldiner, A. R.; Siegbahn, A.; Spector, T. D.; Stefansson, K.; Strachan, D. P.; Tayo, B. O.; Tremoli, E.; Tuomilehto, J.; Uusitupa, M.; van Duijn, C. M.; Vollenweider, P.; Wallentin, L.; Wareham, N. J.; Whitfield, J. B.; Wolffenbuttel, B. H.; Altshuler, D.; Ordovas, J. M.; Boerwinkle, E.; Palmer, C. N.; Thorsteinsdottir, U.; Chasman, D. I.; Rotter, J. I.; Franks, P. W.; Ripatti, S.; Cupples, L. A.; Sandhu, M. S.; Rich, S. S.; Boehnke, M.; Deloukas, P.; Mohlke, K. L.; Ingelsson, E.; Abecasis, G. R.; Daly, M. J.; Neale, B. M.; Kathiresan, S. Common variants associated with plasma triglycerides and risk for coronary artery disease Nat. Genet. 2013, 45 (11) 1345-1352 10.1038/ng.2795
6. Goldberg, I. J.; Eckel, R. H.; McPherson, R. Triglycerides and heart disease: still a hypothesis? Arterioscler., Thromb., Vasc. Biol. 2011, 31 (8) 1716-1725 10.1161/ATVBAHA.111.226100
7. ACCORD Study Group; Ginsberg, H. N.; Elam, M. B.; Lovato, L. C.; Crouse, J. R., III; Leiter, L. A.; Linz, P.; Friedewald, W. T.; Buse, J. B.; Gerstein, H. C.; Probstfield, J.; Grimm, R. H.; Ismail-Beigi, F.; Bigger, J. T.; Goff, D. C., Jr.; Cushman, W. C.; Simons-Morton, D. G.; Byington, R. P. Effects of combination lipid therapy in type 2 diabetes mellitus N. Engl. J. Med. 2010, 362 (17) 1563-1574 10.1056/NEJMoa1001282
8. Jorgensen, A. B.; Frikke-Schmidt, R.; Nordestgaard, B. G.; Tybjaerg-Hansen, A. Loss-of-function mutations in APOC3 and risk of ischemic vascular disease N. Engl. J. Med. 2014, 371 (1) 32-41 10.1056/NEJMoa1308027
9. The TG and HDL Working Group of the Exome Sequencing Project, National Heart, Lung, and Blood Institute; Crosby, J.; Peloso, G. M.; Auer, P. L.; Crosslin, D. R.; Stitziel, N. O.; Lange, L. A.; Lu, Y.; Tang, Z. Z.; Zhang, H.; Hindy, G.; Masca, N.; Stirrups, K.; Kanoni, S.; Do, R.; Jun, G.; Hu, Y.; Kang, H. M.; Xue, C.; Goel, A.; Farrall, M.; Duga, S.; Merlini, P. A.; Asselta, R.; Girelli, D.; Olivieri, O.; Martinelli, N.; Yin, W.; Reilly, D.; Speliotes, E.; Fox, C. S.; Hveem, K.; Holmen, O. L.; Nikpay, M.; Farlow, D. N.; Assimes, T. L.; Franceschini, N.; Robinson, J.; North, K. E.; Martin, L. W.; DePristo, M.; Gupta, N.; Escher, S. A.; Jansson, J. H.; Van Zuydam, N.; Palmer, C. N.; Wareham, N.; Koch, W.; Meitinger, T.; Peters, A.; Lieb, W.; Erbel, R.; Konig, I. R.; Kruppa, J.; Degenhardt, F.; Gottesman, O.; Bottinger, E. P.; O'Donnell, C. J.; Psaty, B. M.; Ballantyne, C. M.; Abecasis, G.; Ordovas, J. M.; Melander, O.; Watkins, H.; Orho-Melander, M.; Ardissino, D.; Loos, R. J.; McPherson, R.; Willer, C. J.; Erdmann, J.; Hall, A. S.; Samani, N. J.; Deloukas, P.; Schunkert, H.; Wilson, J. G.; Kooperberg, C.; Rich, S. S.; Tracy, R. P.; Lin, D. Y.; Altshuler, D.; Gabriel, S.; Nickerson, D. A.; Jarvik, G. P.; Cupples, L. A.; Reiner, A. P.; Boerwinkle, E.; Kathiresan, S. Loss-of-function mutations in APOC3, triglycerides, and coronary disease N. Engl. J. Med. 2014, 371 (1) 22-31 10.1056/NEJMoa1307095
10. Bell, D. A.; Hooper, A. J.; Burnett, J. R. Mipomersen, an antisense apolipoprotein B synthesis inhibitor Expert Opin. Invest. Drugs 2011, 20 (2) 265-272 10.1517/13543784.2011.547471
11. Cuchel, M.; Rader, D. J. Microsomal transfer protein inhibition in humans Curr. Opin. Lipidol. 2013, 24 (3) 246-250 10.1097/MOL.0b013e32836139df
12. Yen, C. L.; Stone, S. J.; Koliwad, S.; Harris, C.; Farese, R. V., Jr. Thematic review series: glycerolipids. DGAT enzymes and triacylglycerol biosynthesis J. Lipid Res. 2008, 49 (11) 2283-2301 10.1194/jlr.R800018-JLR200
13. Zammit, V. A. Hepatic triacylglycerol synthesis and secretion: DGAT2 as the link between glycaemia and triglyceridaemia Biochem. J. 2013, 451 (1) 1-12 10.1042/BJ20121689
14. Turchetto-Zolet, A. C.; Maraschin, F. S.; de Morais, G. L.; Cagliari, A.; Andrade, C. M.; Margis-Pinheiro, M.; Margis, R. Evolutionary view of acyl-CoA diacylglycerol acyltransferase (DGAT), a key enzyme in neutral lipid biosynthesis BMC Evol. Biol. 2011, 11, 263 10.1186/1471-2148-11-263
15. Cases, S.; Stone, S. J.; Zhou, P.; Yen, E.; Tow, B.; Lardizabal, K. D.; Voelker, T.; Farese, R. V., Jr. Cloning of DGAT2, a second mammalian diacylglycerol acyltransferase, and related family members J. Biol. Chem. 2001, 276 (42) 38870-38876 10.1074/jbc.M106219200
16. Yen, C. L. E.; Monetti, M.; Burri, B. J.; Farese, R. V., Jr. The triacylglycerol synthesis enzyme DGAT1 also catalyzes the synthesis of diacylglycerols, waxes, and retinyl esters J. Lipid Res. 2005, 46 (7) 1502-1511 10.1194/jlr.M500036-JLR200
17. Devita, R. J.; Pinto, S. Current Status of the Research and Development of Diacylglycerol O-Acyltransferase 1 (DGAT1) Inhibitors J. Med. Chem. 2013, 56 (24) 9820-9825 10.1021/jm4007033
18. Naik, R.; Obiang-Obounou, B. W.; Kim, M.; Choi, Y.; Lee, H. S.; Lee, K. Therapeutic Strategies for Metabolic Diseases: Small-Molecule Diacylglycerol Acyltransferase (DGAT) Inhibitors ChemMedChem 2014, 9 (11) 2410-2424 10.1002/cmdc.201402069
19. Denison, H.; Nilsson, C.; Lofgren, L.; Himmelmann, A.; Martensson, G.; Knutsson, M.; Al-Shurbaji, A.; Tornqvist, H.; Eriksson, J. W. Diacylglycerol acyltransferase 1 inhibition with AZD7687 alters lipid handling and hormone secretion in the gut with intolerable side effects: a randomized clinical trial Diabetes, Obes. Metab. 2014, 16 (4) 334-343 10.1111/dom.12221
20. Maciejewski, B. S.; LaPerle, J. L.; Chen, D.; Ghosh, A.; Zavadoski, W. J.; McDonald, T. S.; Manion, T. B.; Mather, D.; Patterson, T. A.; Hanna, M.; Watkins, S.; Gibbs, E. M.; Calle, R. A.; Steppan, C. M. Pharmacological inhibition to examine the role of DGAT1 in dietary lipid absorption in rodents and humans Am. J. Physiol Gastrointest Liver Physiol 2013, 304 (11) G958-G969 10.1152/ajpgi.00384.2012
21. A 12-week multi-center, randomized, double-blind, placebo-controlled, parallel-group adaptive design study to evaluate the efficacy on blood glucose control and safety of five doses of LCQ908 (2, 5, 10, 15 and 20 mg) or sitagliptin 100 mg on a background therapy of metformin in obese patients with type 2 diabetes. Clinical Trial Results Database; Novartis, 2010; http://www.novctrd.com/ctrdWebApp/clinicaltrialrepository/displayFile.do?trialResult=4313.
22. Stone, S. J.; Myers, H. M.; Watkins, S. M.; Brown, B. E.; Feingold, K. R.; Elias, P. M.; Farese, R. V., Jr. Lipopenia and skin barrier abnormalities in DGAT2-deficient mice J. Biol. Chem. 2004, 279 (12) 11767-11776 10.1074/jbc.M311000200
23. Choi, C. S.; Savage, D. B.; Kulkarni, A.; Yu, X. X.; Liu, Z. X.; Morino, K.; Kim, S.; Distefano, A.; Samuel, V. T.; Neschen, S.; Zhang, D.; Wang, A.; Zhang, X. M.; Kahn, M.; Cline, G. W.; Pandey, S. K.; Geisler, J. G.; Bhanot, S.; Monia, B. P.; Shulman, G. I. Suppression of diacylglycerol acyltransferase-2 (DGAT2), but not DGAT1, with antisense oligonucleotides reverses diet-induced hepatic steatosis and insulin resistance J. Biol. Chem. 2007, 282 (31) 22678-22688 10.1074/jbc.M704213200
24. Liu, Y.; Millar, J. S.; Cromley, D. A.; Graham, M.; Crooke, R.; Billheimer, J. T.; Rader, D. J. Knockdown of acyl-CoA:diacylglycerol acyltransferase 2 with antisense oligonucleotide reduces VLDL TG and ApoB secretion in mice Biochim. Biophys. Acta, Mol. Cell Biol. Lipids 2008, 1781 (3) 97-104 10.1016/j.bbalip.2008.01.001
25. Yu, X. X.; Murray, S. F.; Pandey, S. K.; Booten, S. L.; Bao, D.; Song, X. Z.; Kelly, S.; Chen, S.; McKay, R.; Monia, B. P.; Bhanot, S. Antisense oligonucleotide reduction of DGAT2 expression improves hepatic steatosis and hyperlipidemia in obese mice Hepatology 2005, 42 (2) 362-371 10.1002/hep.20783
26. Kim, M. O.; Lee, S.; Choi, K.; Lee, S.; Kim, H.; Kang, H.; Choi, M.; Kwon, E. B.; Kang, M. J.; Kim, S.; Lee, H.-J.; Lee, H. S.; Kwak, Y.-S.; Cho, S. Discovery of a Novel Class of Diacylglycerol Acyltransferase 2 Inhibitors with a 1H-Pyrrolo[2,3-b]Pyridine Core Biol. Pharm. Bull. 2014, 37 (10) 1655-1660 10.1248/bpb.b14-00447
27. Lee, K.; Kim, M.; Lee, B.; Goo, J.; Kim, J.; Naik, R.; Seo, J. H.; Kim, M. O.; Byun, Y.; Song, G. Y.; Lee, H. S.; Choi, Y. Discovery of indolyl acrylamide derivatives as human diacylglycerol acyltransferase-2 selective inhibitors Org. Biomol. Chem. 2013, 11 (5) 849-858 10.1039/C2OB27114A
28. Kim, M. O.; Lee, S. U.; Lee, H. J.; Choi, K.; Kim, H.; Lee, S.; Oh, S. J.; Kim, S.; Kang, J. S.; Lee, H. S.; Kwak, Y. S.; Cho, S. Identification and validation of a selective small molecule inhibitor targeting the diacylglycerol acyltransferase 2 activity Biol. Pharm. Bull. 2013, 36 (7) 1167-1173 10.1248/bpb.b13-00152
29. Wurie, H. R.; Buckett, L.; Zammit, V. A. Diacylglycerol acyltransferase 2 acts upstream of diacylglycerol acyltransferase 1 and utilizes nascent diglycerides and de novo synthesized fatty acids in HepG2 cells FEBS J. 2012, 279 (17) 3033-3047 10.1111/j.1742-4658.2012.08684.x
30. Qi, J.; Lang, W.; Geisler, J. G.; Wang, P.; Petrounia, I.; Mai, S.; Smith, C.; Askari, H.; Struble, G. T.; Williams, R.; Bhanot, S.; Monia, B. P.; Bayoumy, S.; Grant, E.; Caldwell, G. W.; Todd, M. J.; Liang, Y.; Gaul, M. D.; Demarest, K. T.; Connelly, M. A. The use of stable isotope-labeled glycerol and oleic acid to differentiate the hepatic functions of DGAT1 and -2 J. Lipid Res. 2012, 53 (6) 1106-1116 10.1194/jlr.M020156
31. During the preparation of this manuscript, a patent application was published by Eli Lilly on pyrimidine-based DGAT2 inhibitors showing in vivo pharmacology in rodent models. Camp, N. P.; Naik, M. Novel DGAT2 inhibitors. PCT Int. Appl. WO2015077299, 2015.
32. Yang, D.; Fokas, D.; Li, J.; Yu, L.; Baldino, C. M. A Versatile Method for the Synthesis of Benzimidazoles from o-Nitroanilines and Aldehydes in One Step via a Reductive Cyclization Synthesis 2005, 1, 47-56 10.1055/s-2004-834926
33. Ivanova, N. V.; Sviridov, S. I.; Stepanov, A. E. Parallel solution-phase synthesis of substituted 2-(1,2,4-triazol-3-yl)benzimidazoles Tetrahedron Lett. 2006, 47 (46) 8025-8027 10.1016/j.tetlet.2006.09.061
34. Lin, S.; Yang, L. A simple and efficient procedure for the synthesis of benzimidazoles using air as the oxidant Tetrahedron Lett. 2005, 46 (25) 4315-4319 10.1016/j.tetlet.2005.04.101
35. Lin, S.-Y.; Isome, Y.; Stewart, E.; Liu, J.-F.; Yohannes, D.; Yu, L. Microwave-assisted one step high-throughput synthesis of benzimidazoles Tetrahedron Lett. 2006, 47 (17) 2883-2886 10.1016/j.tetlet.2006.02.127
36. Guillaume, D.; Brum-Bousquet, M.; Aitken, D. J.; Husson, H.-P. Cyclopropanation of dibenylaminoacetonitrile: evaluation of 1,2-dibromides and cyclic 1,2-sulfates as dielectrophiles Bull. Soc. Chim. Fr. 1994, 131, 391-396
37. McFie, P. J.; Stone, S. J. A fluorescent assay to quantitatively measure in vitro acyl CoA:diacylglycerol acyltransferase activity J. Lipid Res. 2011, 52 (9) 1760-1764 10.1194/jlr.D016626
38. Harris, C. A.; Haas, J. T.; Streeper, R. S.; Stone, S. J.; Kumari, M.; Yang, K.; Han, X.; Brownell, N.; Gross, R. W.; Zechner, R.; Farese, R. V., Jr. DGAT enzymes are required for triacylglycerol synthesis and lipid droplets in adipocytes J. Lipid Res. 2011, 52 (4) 657-667 10.1194/jlr.M013003
39. Cao, J.; Cheng, L.; Shi, Y. Catalytic properties of MGAT3, a putative triacylgycerol synthase J. Lipid Res. 2007, 48 (3) 583-591 10.1194/jlr.M600331-JLR200
40. Yen, C. L.; Farese, R. V., Jr. MGAT2, a monoacylglycerol acyltransferase expressed in the small intestine J. Biol. Chem. 2003, 278 (20) 18532-18537 10.1074/jbc.M301633200
41. Yen, C. L.; Stone, S. J.; Cases, S.; Zhou, P.; Farese, R. V., Jr. Identification of a gene encoding MGAT1, a monoacylglycerol acyltransferase Proc. Natl. Acad. Sci. U. S. A. 2002, 99 (13) 8512-8517 10.1073/pnas.132274899
42. Shultz, M. D. Setting expectations in molecular optimizations: Strengths and limitations of commonly used composite parameters Bioorg. Med. Chem. Lett. 2013, 23 (21) 5980-5991 10.1016/j.bmcl.2013.08.029
43. Freeman-Cook, K. D.; Hoffman, R. L.; Johnson, T. W. Lipophilic efficiency: the most important efficiency metric in medicinal chemistry Future Med. Chem. 2013, 5 (2) 113-115 10.4155/fmc.12.208
44. Tarcsay, A.; Nyiri, K.; Keseru, G. M. Impact of Lipophilic Efficiency on Compound Quality J. Med. Chem. 2012, 55 (3) 1252-1260 10.1021/jm201388p
45. Leeson, P. D.; Empfield, J. R. Reducing the risk of drug attrition associated with physicochemical properties Annu. Rep. Med. Chem. 2010, 45, 393-407 10.1016/S0065-7743(10)45024-1
46. Edwards, M. P.; Price, D. A. Role of Physicochemical Properties and Ligand Lipophilicity Efficiency in Addressing Drug Safety Risks Annu. Rep. Med. Chem. 2010, 45, 380-391 10.1016/S0065-7743(10)45023-X
47. Lombardo, F.; Shalaeva, M. Y.; Tupper, K. A.; Gao, F. ElogD(oct): a tool for lipophilicity determination in drug discovery. 2. Basic and neutral compounds J. Med. Chem. 2001, 44 (15) 2490-2497 10.1021/jm0100990
48. Di, L.; Keefer, C.; Scott, D. O.; Strelevitz, T. J.; Chang, G.; Bi, Y. A.; Lai, Y.; Duckworth, J.; Fenner, K.; Troutman, M. D.; Obach, R. S. Mechanistic insights from comparing intrinsic clearance values between human liver microsomes and hepatocytes to guide drug design Eur. J. Med. Chem. 2012, 57, 441-448 10.1016/j.ejmech.2012.06.043
49. Walsky, R. L.; Bauman, J. N.; Bourcier, K.; Giddens, G.; Lapham, K.; Negahban, A.; Ryder, T. F.; Obach, R. S.; Hyland, R.; Goosen, T. C. Optimized assays for human UDP-glucuronosyltransferase (UGT) activities: altered alamethicin concentration and utility to screen for UGT inhibitors Drug Metab. Dispos. 2012, 40 (5) 1051-1065 10.1124/dmd.111.043117
50. Gill, K. L.; Houston, J. B.; Galetin, A. Characterization of in vitro glucuronidation clearance of a range of drugs in human kidney microsomes: comparison with liver and intestinal glucuronidation and impact of albumin Drug Metab. Dispos. 2012, 40 (4) 825-835 10.1124/dmd.111.043984
51. Kilford, P. J.; Stringer, R.; Sohal, B.; Houston, J. B.; Galetin, A. Prediction of drug clearance by glucuronidation from in vitro data: use of combined cytochrome P450 and UDP-glucuronosyltransferase cofactors in alamethicin-activated human liver microsomes Drug Metab. Dispos. 2009, 37 (1) 82-89 10.1124/dmd.108.023853
52. Rowland, A.; Knights, K. M.; Mackenzie, P. I.; Miners, J. O. The "albumin effect" and drug glucuronidation: bovine serum albumin and fatty acid-free human serum albumin enhance the glucuronidation of UDP-glucuronosyltransferase (UGT) 1A9 substrates but not UGT1A1 and UGT1A6 activities Drug Metab. Dispos. 2008, 36 (6) 1056-1062 10.1124/dmd.108.021105
53. Kaivosaari, S.; Finel, M.; Koskinen, M. N-glucuronidation of drugs and other xenobiotics by human and animal UDP-glucuronosyltransferases Xenobiotica 2011, 41 (8) 652-669 10.3109/00498254.2011.563327
54. Lovering, F. Escape from Flatland 2: complexity and promiscuity MedChemComm 2013, 4 (3) 515-519 10.1039/c2md20347b
55. Rose, K.; Yang, Y.-S.; Sciotti, R.; Cai, H. Structure-activity relationship (SAR): effort towards blocking N-glucuronidation of indazoles (PF-03376056) by human UGT1A enzymes Drug Metab. Lett. 2009, 3 (1) 28-34 10.2174/187231209787176371
56. Dow, R. L.; Li, J.-C.; Pence, M. P.; Gibbs, E. M.; LaPerle, J. L.; Litchfield, J.; Piotrowski, D. W.; Munchhof, M. J.; Manion, T. B.; Zavadoski, W. J.; Walker, G. S.; McPherson, R. K.; Tapley, S.; Sugarman, E.; Guzman-Perez, A.; DaSilva-Jardine, P. Discovery of PF-04620110, a Potent, Selective, and Orally Bioavailable Inhibitor of DGAT-1 ACS Med. Chem. Lett. 2011, 2 (5) 407-412 10.1021/ml200051p
57. Ishibashi, S.; Brown, M. S.; Goldstein, J. L.; Gerard, R. D.; Hammer, R. E.; Herz, J. Hypercholesterolemia in low density lipoprotein receptor knockout mice and its reversal by adenovirus-mediated gene delivery J. Clin. Invest. 1993, 92 (2) 883-893 10.1172/JCI116663
58. Cuchel, M.; Bloedon, L. T.; Szapary, P. O.; Kolansky, D. M.; Wolfe, M. L.; Sarkis, A.; Millar, J. S.; Ikewaki, K.; Siegelman, E. S.; Gregg, R. E.; Rader, D. J. Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia N. Engl. J. Med. 2007, 356 (2) 148-156 10.1056/NEJMoa061189
59. Gerdes, L. U.; Gerdes, C.; Klausen, I. C.; Faergeman, O. Generation of analytic plasma lipoprotein profiles using two prepacked superose 6B columns Clin. Chim. Acta 1992, 205 (1-2) 1-9 10.1016/0009-8981(92)90348-T
60. Folch, J.; Lees, M.; Sloane Stanley, G. H. A simple method for the isolation and purification of total lipides from animal tissues J. Biol. Chem. 1957, 226 (1) 497-509
61. Kaluzny, M. A.; Duncan, L. A.; Merritt, M. V.; Epps, D. E. Rapid separation of lipid classes in high yield and purity using bonded phase columns J. Lipid Res. 1985, 26 (1) 135-140
62. El-Hamdy, A. H.; Christie, W. W. Separation of non-polar lipids by high performance liquid chromatography on a cyanopropyl column J. High Resolut. Chromatogr. 1993, 16 (1) 55-57 10.1002/jhrc.1240160112